Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib with or without apatinib versus investigator's choice chemotherapy for breast cancer
CTR20200375Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of fluzoparib, Rivoceranib in breast cancer, sponsored by Hengrui Therapeutics. Started Jul 2020; status: active.
02
Drugs
fluzoparibRivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20200375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200375.